Renal Cell Carcinoma (RCC) research hub
31 indexed studies · 21 currently recruiting
- recruitingPHASE1
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This study is testing a new drug, zanzalintinib, alone and with other medicines, for people with advanced cancers like kidney, prostate, and lung cancer. It's looking at safety and if the treatment shrinks tumours.
United States · Australia · Austria - recruitingPHASE1, PHASE2
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
This study is testing a new drug called CRB-601, along with existing immunotherapy, for people with advanced solid tumors that haven't responded to other treatments. The aim is to check its safety, how it works in the body, and if it helps shrink tumors.
United States · United Kingdom - recruitingPHASE1
A Study of PYX-201 in Advanced Solid Tumors
This study is testing a new medicine, PYX-201, for people with advanced solid cancers. Doctors want to find the best dose and see if it shrinks tumours. It's an early-stage study to understand how safe and effective the medicine is.
United States · Belgium · Spain - recruitingPHASE1
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
This study is testing a new drug, GDC-7035, for people with advanced solid tumours that have a specific genetic change called KRAS G12D. Researchers want to see if it's safe, how it works in the body, and if it helps shrink tumours, both on its own and with other treatments.
United States · Australia · Canada - active not recruitingPHASE4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
This study helps people with certain cancers or GvHD who are already taking ibrutinib and benefiting from it. It allows them to keep getting the medication if they can't get it commercially and helps researchers learn more about its long-term use.
United States · Australia · Canada - recruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
United States · Denmark · Hong Kong - recruitingPHASE3
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
This study looks at the continued safety and benefit of a medicine called pelabresib for people with blood or solid cancers. It's for those who have used pelabresib before in other studies.
United States · Belgium · Italy - active not recruitingPHASE1
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
This study looks at a new drug, Inavolisib, for people with solid tumours or breast cancer, focusing on safety and how the body handles it. It's an early-stage study, checking if the drug works alone or with other common cancer treatments.
United States · Canada · France - recruitingPHASE1, PHASE2
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
This study is testing a new drug, NUC-7738, for people with advanced cancers like solid tumours and lymphoma. It aims to see how safe the drug is, how it works in the body, and if it helps treat these cancers, sometimes combined with pembrolizumab.
United Kingdom - recruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
This study is testing a new drug, Farletuzumab Ecteribulin, for certain advanced cancers like ovarian, endometrial, and some breast and lung cancers. Researchers want to see if it's safe, how well it works, and find the best dose.
United States · France · Japan - recruitingPHASE1, PHASE2
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
This study looks at a medicine called pembrolizumab for children aged 6 months to 17 years with certain advanced cancers that haven't responded to other treatments. It's an immunotherapy that helps the body's immune system fight cancer, and researchers want to see if it can shrink these cancers.
United States · Brazil · France - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors
This study is testing a new medicine, BMS-986360/CC-90001, for people with advanced solid cancers. It will see how safe the medicine is when given alone or with other cancer treatments like chemotherapy or nivolumab. It's an early-stage study, meaning it's the first time it will be widely used in people.
Italy · Spain · France - recruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This study is testing a new medicine, TH9619, for people with advanced cancers like bowel, head and neck, lung, and stomach cancer. It's the first time TH9619 is being given to people, and doctors want to find the safest and most effective dose.
France · Spain · United Kingdom - active not recruitingPHASE2
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations
This study looks at new drug combinations, binimetinib and encorafenib, for people with advanced cancers. It focuses on specific gene changes (BRAF mutations) that haven't responded to other treatments, aiming to see how well these drugs shrink tumors.
Canada - recruitingPHASE1, PHASE2
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
This study looks at a new treatment called 177Lu-FAP-2286 for advanced solid cancers. It aims to find a safe dose and see how well it works. This treatment targets a specific protein found on many cancer cells.
United States · Australia · Canada - recruitingPHASE1
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
This study is testing a new drug, ASP5834, for adults with certain solid cancers. It aims to find the right dose and check for side effects, sometimes given with another cancer drug called panitumumab, especially for bowel cancer.
United States · France · Japan - recruitingPHASE1, PHASE2
Ixovex-1 Single Agent and Combination Therapy
This study is testing a new virus treatment, Ixovex-1, for advanced solid tumours and head and neck cancer. It aims to find a safe dose, alone and with Pembrolizumab, for patients who have limited other treatment options.
United Kingdom - recruitingPHASE1
A Study of ASP3082 in Adults With Advanced Solid Tumors
This study looks at a new drug, ASP3082, for adults with advanced solid cancers that have a specific genetic change called KRAS G12D. It checks how safe the drug is and what dose works best, sometimes with another drug called cetuximab.
United States · China · France - active not recruitingPHASE1
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
This study is testing a new drug, BYON4228, sometimes with another drug called pembrolizumab, for people with advanced solid tumours. It aims to find the right dose and see how safe and effective this treatment is.
Belgium · Spain · United Kingdom - recruitingPHASE4
Dabrafenib and/or Trametinib Rollover Study
This study allows patients already on dabrafenib and/or trametinib for certain cancers to continue treatment if their doctor thinks it's helping and they meet specific criteria. It's for people already in another study.
United States · Argentina · Austria - recruiting
Immune Resistance Interrogation Study
This study looks at why some cancers stop responding to immunotherapy. We collect tumour samples, blood, and stool from patients who had immunotherapy to understand how their bodies react differently.
Canada - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors
This early-stage study is testing a new drug, INCB099280, combined with an existing cancer treatment, YERVOY, for solid tumours. Researchers want to see if this combination causes any serious side effects and how much of the new drug stays in the body. It's a first step to understand safety.
Sweden · Norway · Slovakia - recruiting
Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
This study looks at how tiny germs in your gut and certain blood markers might predict side effects from new cancer drugs called immunotherapies. It hopes to find ways to better manage these side effects in people with advanced cancer.
Canada - recruitingPHASE1
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
This study is testing a new cell therapy and a vaccine for people with advanced solid tumors. It aims to find out how safe they are and if they can help shrink tumors that have a specific marker called CLDN6.
Australia · Germany · Netherlands - recruitingNA
Effects of Neoadjuvant Prehabilitation on Post-Interventional Physical and Psychological Outcomes in Oncology Patients With Solid Tumors
This study looks at how a special program of exercise and emotional support before cancer treatment might help people with solid tumours, especially breast cancer. Researchers want to see if this program improves how people feel, both physically and emotionally, compared to usual care.
Germany - recruitingNA
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
This study, MAPPYACTS 2, helps doctors in France find the best treatments for children and young adults with cancer that has come back or isn't responding. It uses special tests to look closely at cancer cells to suggest personalised treatment options.
France - active not recruitingPHASE1, PHASE2
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
This study is testing a new drug called neratinib for children and young adults with cancer that has come back or not responded to other treatments. The main goals are to find a safe dose and understand its effects on the cancer and patients.
United States · Canada - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Phase 1 Study of BMS-986416 with and without Nivolumab in Solid Tumors
This study is looking at a new medicine called BMS-986416, sometimes given with another drug called Nivolumab, for people with solid tumours. It's a very early-stage study to see how safe the drug is and how it works in the body.
Belgium · Netherlands - active not recruitingPHASE1, PHASE2
A Trial of Ipatasertib in Combination With Atezolizumab
This study looks at combining two medicines, ipatasertib and atezolizumab, for advanced solid tumours and a type of brain tumour called glioblastoma. It aims to find the safest dose and see how well they work together. It's a early-stage study to understand more about these treatments.
United Kingdom - recruitingPHASE1
Study of STP938 (Dencatistat) in Advanced Solid Tumours
This study is testing a new drug called STP938 for people with advanced solid tumours that haven't responded to other treatments. It aims to find the right dose and check how safe the drug is when given alone.
United States · France · United Kingdom - active not recruitingPHASE1
Study of GS-4528 in Adults With Solid Tumors
This study is testing a new drug, GS-4528, on its own or with another drug, Zimberelimab, for adults with solid cancers. Researchers want to find out if it's safe, what dose works best, and if people can tolerate it.
United States · Canada · South Korea